ONCAlert | Upfront Therapy for mRCC
Videos  >  

CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Natalie S. Grover, MD
Published Online:8:56 PM, Tue March 5, 2019

Natalie S. Grover, MD, assistant professor at the University of North Carolina Chapel Hill, discusses the potential role of CD30-specific chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory Hodgkin lymphoma.

While the majority of patients treated in the first-line setting will do well, there is still a portion of patients that have refractory disease, Grover says. While there are great treatment options available, including brentuximab vedotin (Adcetris), and checkpoint inhibitors, these are still not curative.

Many patients will need to undergo allogeneic stem cell transplant for cure, but this treatment is associated with a high morbidity and mortality. Grover says that CD30-specific CAR T cells may be a promising option for these patients that could provide a longer duration of response and remission.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.